Carolina Panthers tight end Ja'Tavion Sanders was taken to a hospital for a neck injury after landing on his head while making a catch late in the first half of Sunday's 30-27 home loss to the Kansas City Chiefs. As Sanders was brought down near the sideline after a 10-yard reception, he was flipped upside down and landed directly on the top of his helmet as he went out of bounds on the tackle by cornerback Trent McDuffie. After receiving attention from the team's medical staff, Sanders was strapped to a backboard and taken off the field on a cart with 40 seconds remaining in the half. He was taken to Atrium Health Carolinas Medical Center in Charlotte for observation and later released Sunday afternoon, according to the team. On the CBS broadcast following halftime, Panthers head coach Dave Canales said Sanders had movement in all his extremities, while extreme precaution was taken because of back tightness. CBS reported he was being examined for a concussion before later amending that to a neck injury. The 21-year-old rookie out of Texas had a team-leading three receptions for the Panthers at the half for 49 yards. In 11 games this season, Sanders has 29 receptions for 302 yards and a touchdown. Sanders was a fourth-round selection in the NFL draft in April. --Field Level MediaDocusign Announces Third Quarter Fiscal 2025 Financial Results
BRASILIA, Brazil (AP) — Supermarket giant Carrefour’s support for French farmers’ protests against a trade agreement between the European Union and the South American bloc Mercosur has sparked a strong reaction in Brazil, including a refusal to supply beef to Carrefour stores in Brazil. Carrefour CEO Alexandre Bompard announced in social media posts last week that the French company would stop buying beef from all Mercosur countries, which also include Argentina, Paraguay and Uruguay. Bompard wrote that he agrees with French producers' arguments that Mercosur beef is an unfair competitor due to lower production costs resulting from fewer environmental and sanitary requirements. The executive encouraged other retailers to follow suit. Brazil's Ministry of Agriculture called Bompard's move protectionist, saying it was made “without any technical criteria.” The decision also angered Brazil's meatpackers. Though France makes up just a tiny sliver of Brazil’s beef exports, meatpackers worried that Carrefour’s decision would hurt its reputation in other markets. Beef giants JBS and Marfrig halted supplies last Friday to Carrefour's extensive supermarket chain in Brazil, including the food warehouse giant Atacadao. Both companies refused to comment on the boycott to The Associated Press, but Minister of Agriculture Carlos Fávaro confirmed it. “We support the reaction of the meatpackers. If Brazil ́s beef isn’t good enough for Carrefour’s shelves in France, it isn’t good enough for Carrefour’s shelves in Brazil either,” Faváro told Folha de S.Paulo newspaper on Monday. Carrefour Group in Brazil acknowledged the boycott in a statement, though it said there's not yet a shortage of beef in stores. It said it has “esteem and confidence in the Brazilian agricultural sector, with which it maintains a solid relationship and partnership.” “Unfortunately, the decision to suspend the meat supply has an impact on customers, especially those who rely on the company to supply their homes with quality and responsible products,” the statement said. “It is in constant dialogue in search of solutions that will make it possible to resume the supply of meat to its stores as quickly as possible, respecting the commitments it has to its more than 130,000 Brazilian employees and millions of Brazilian customers countrywide.” The backdrop for the conflict is the EU-Mercosur trade deal , which would increase agricultural imports to EU countries from South America. French farmers fear it will affect their livelihoods. An initial agreement was reached in 2019, but negotiations have faltered since then due to opposition that also includes some European governments. Brazil’s agribusiness sector also fears that the pending European Union Deforestation Regulation will outlaw the sale of forest-derived products within the EU’s 27-nation bloc if companies can’t prove their goods are not linked to deforestation. Its scope includes soy and cattle, Brazil’s top agricultural exports. Almost half of the country’s cattle is raised in the Amazon region, where 90% of deforested land since 1985 has turned into pasture, according to MapBiomas, a nonprofit network. The date of its implementation remains uncertain. The Associated Press’ climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP’s standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org .
FDA Grants IDE Approval for the Pivotal Trial of the JuxtaFlow® Renal Assist Device (RAD)FDA Grants IDE Approval for the Pivotal Trial of the JuxtaFlow® Renal Assist Device (RAD)
SFA president Mike Mulraney has stressed he is determined for the governing body to maintain a strong working relationship with major “economic driver” Rangers after launching an ambitious £50m campaign to upgrade 90 football pitches and 75 dressing rooms across Scotland by 2030. Mulraney and SPFL chief executive Neil Doncaster helped to facilitate the Ibrox club’s temporary relocation to Hampden back in July when redevelopment work on the Copland Stand ran over schedule due, despite written guarantees the materials were in place from the contractors, to a delay in a shipment of steel from Asia. The Alloa honorary president rubbished suggestions his organisation are at loggerheads with the Glasgow giants as the controversy over the Vaclav Cerny penalty incident in their Premier Sports Cup final against Celtic, who lifted the trophy after a dramatic spot kick shootout, on Sunday rumbled on. Relations between the SFA and Rangers have often been strained in recent years and the outcry over the failure by VAR officials Alan Muir and Frank Connor to spot that Cerny had entered the opposition area while he was being pulled by Liam Scales has led to renewed claims that ill-feeling persists behind the scenes. However, Mulraney, who was at the home of Pollok United in Glasgow on Wednesday to get the Pitching In project underway with a donation of £5m, stressed that he has been personally incensed at refereeing decisions which have gone against his own club in the past and has asked for clarification. Read more: Rangers and Celtic pyro disciplinary takes new Safety Officer twist Celtic defender responds to Rangers VAR penalty outrage Sir Jim Ratcliffe increases Manchester United stake The businessman knows that his crusade to improve facilities for footballers of all ages and abilities across Scotland in the next six years depends on all the clubs in the country working as one for the greater good of the game and he is eager to have Rangers on board. “I can only speak personally and say that since I have been involved with the SFA I have had pretty good relationship with most clubs,” he said. “Often it’s about letting people know that your door is open. They don’t even have to walk through it so long as they know it is open and we certainly have that attitude. “It’s having a positive impact. We can’t improve facilities unless we have our senior clubs on board. Senior clubs drive the economy of Scottish football. They are the big motors behind the economy of our game. “If I want Ian [chief executive Maxwell] to produce £7m profit for the SFA when other sports are struggling then we need our big economic drivers to be on board. To allow us to use that money to do good. So we have a really good relationship, I believe, with our partners and our members.” (Image: SNS) Mulraney continued: “It’s not Rangers, Celtic, Aberdeen and Dundee United against the SFA. They are the SFA. They are the members, they are the owners. This idea that they are going to demand talks. Who with? Themselves? I am there to represent them, I am them, I am one of them. “When I had my Alloa hat on and we didn’t get a penalty I thought we should have had I got as upset as anyone. I didn’t get as many column inches. But I was on the phone asking, ‘How come my boy got sent off?’ “That’s the passion of football and I hope it never goes away. I want everybody to be up for what happened at the weekend. Now, I want success and I don’t want mistakes to be made, but I want the theatre of our game. It’s fantastic. “But, remember, when clubs ask for discussion it’s with themselves. They are us and we are them and we’re in it together. The reason we sit here today is so that we can talk and say, ‘This is what we are trying to do’. “To build the infrastructure we need money, and to get money we need Rangers, we need Celtic, we need Aberdeen, Hearts, Livingston, Annan, Elgin, Peterhead and Sauchie Juniors. We need everybody on board.” Read more: Rangers respond after Willie Collum major VAR error admission Willie Collum admits 'unacceptable' Rangers cup final penalty mistake The Rangers penalty call that divided SFA & KMI panel SFA head of refereeing Willie Collum contacted Rangers this week to admit that Philippe Clement’s side should have been awarded a penalty for the Scales tug on Cerny and he publicly admitted that when he appeared on The Var Review show on You Tube yesterday lunchtime. However, Mulraney pointed out that the modern technology remains susceptible to human error and stressed that mistakes will still be made in games despite its presence at grounds around the country and the best efforts of staff at Clydesdale House. He is sure that Collum and his colleagues will be devastated that there was such a glaring error was made in such a high profile match and will be redoubling their efforts to ensure that there are no further mistakes in the weeks and months ahead. “Knowing Willie and every single person involved with every decision that’s wrong, it hurts,” he said. “I am not sure it hurts them any more if it is a cup final than any other game. I really don’t think so. “Every ref, linesman, VAR operator, all of them, it hurts them just as much as the centre forward who misses a shot from three yards out, the guy who misses the penalty, the goalie who fumbles the ball into the net and goes home and beats himself up about it. I honestly think that’s the case.”Panthers TE Ja'Tavion Sanders carted off field for neck injury
Sira Thienou scores 16 points, No. 18 Ole Miss women coast to 89-24 win over Alabama StateSempra Named Among Newsweek's 'Most Responsible Companies'
Opinions expressed by Digital Journal contributors are their own Telehealth provider Zealthy has unveiled a $39 introductory package to reshape healthcare accessibility in the United States. This initiative tackles persistent high costs, long wait times, and limited access to primary care providers that plague traditional healthcare systems. Zealthy’s technology-driven system combines advanced platforms with personalized care plans, marking a decisive shift in medical service delivery. Recent studies show approximately 25% of Americans skip necessary medical care due to prohibitive costs. The platform eliminates these financial barriers through transparent pricing while delivering premium medical care to everyone. The platform provides immediate access to healthcare professionals, eliminating delays typical of traditional medical appointments. Research from Harvard Medical School highlights this urgency, showing patients in major U.S. cities wait an average of 24 days for appointments. Zealthy’s specialized telehealth services offer same-day or next-day appointments, dramatically cutting delays and improving patient convenience. Jorge Contreras, spokesperson for Zealthy, explains its purpose: “We’ve built a central hub where people receive top-tier medical care from their homes. Our work focuses on convenient, accessible, and affordable healthcare for everyone.” Measurable patient outcomes demonstrate the effectiveness of Zealthy’s system. Roughly 80% of members report substantial health improvements within three months of starting the service. These numbers demonstrate the value of consistent provider access and ongoing support for better patient health. Zealthy’s digital platform resolves common healthcare frustrations—long wait times, travel challenges, and steep costs. The system connects patients with qualified medical providers in as little as 15 minutes from home, fundamentally changing patient-healthcare interactions. Quick access encourages patients to seek timely medical attention. Patient testimonials reinforce the platform’s effectiveness. Amanda, a current user, describes her smooth experience obtaining birth control online and highlights the platform’s ease of use. Her account shows how the platform’s services improve healthcare access nationwide. In 2023, Zealthy expanded to serve 28 states, delivering services from primary care to specialized weight loss and mental health support programs. The platform provides comprehensive care through remote video visits, prescription delivery, and continuous care team messaging, tailoring treatment to individual patient needs. The company structures its pricing for clarity and affordability. The $39 first-month program includes extensive medical services, covering primary care visits and specialist consultations. Insurance partnerships expand coverage options for both insured and uninsured individuals. Contreras emphasizes pricing transparency, “Our unified telemedicine platform reduces expenses while maintaining high care standards. Clear pricing matters just as much as clear medical communication.” This focus on affordability and quality care establishes Zealthy’s distinct position in healthcare delivery. Zealthy’s platform features sophisticated technology that strengthens patient-provider communication and satisfaction. Intelligent triage systems enable swift care access while secure messaging maintains ongoing patient-provider connections. These technical capabilities contribute to a 95% patient satisfaction rate, exceeding traditional medical care ratings. The company focuses on transforming healthcare accessibility while expanding across the United States. Its full-featured platform, instant medical access, and straightforward pricing structure demonstrate new possibilities in medical care delivery. New members can start with the $39 introductory package, accessing comprehensive services tailored to their needs. This package includes unlimited messaging with care teams, virtual doctor visits, and personalized treatment planning. It harnesses technology to create accessible and affordable options, leading to changes in American healthcare delivery. The launch of Zealthy’s affordable telehealth services addresses critical challenges in American healthcare today. Through innovative solutions and strategic partnerships prioritizing accessibility and affordability, Zealthy leads the movement toward equitable healthcare for all Americans.
Man, smashes Ola scooter after receiving Rs 90,000 bill for repairs
Roivios Initiates Landmark Study to Demonstrate Safety and Efficacy of an Innovative Renal Assist Device for Cardiac Surgery Patients With Kidney Disease NASSAU, Bahamas , Dec. 19, 2024 /PRNewswire/ -- Roivios , a pioneering clinical-stage medical device company dedicated to revolutionizing kidney health, proudly announces that its research and development arm, 3ive Labs, has secured approval for an Investigational Device Exemption (IDE) from the FDA. This approval paves the way for a pivotal trial of the JuxtaFlow Renal Assist Device (RAD), marking a transformative step forward in enhancing outcomes for cardiac surgery patients with renal insufficiency. The GRADIENT ( G roundbreaking R enal A ssist D evice I ntervening to EN hance cardio T horacic surgery outcomes) trial is designed to address the critical need for renal support among cardiac surgery patients undergoing cardiopulmonary bypass (CPB). These patients often face increased risks of postoperative complications, such as worsening renal dysfunction, which can lead to extended ICU stays and increased mortality. "The GRADIENT Trial offers an invaluable opportunity to further explore renal support during cardiac surgery," said Dr. Evelio Rodriguez , a renowned heart surgeon at Ascension Saint Thomas in Nashville, TN , and the National Principal Investigator of the GRADIENT trial. "The JuxtaFlow device offers new hope for some of our most vulnerable patients." JuxtaFlow RAD is an innovative device designed to potentially improve kidney function during times of acute stress. By applying a gentle suction to the kidney's outlet, it aims to enhance blood filtration more efficiently. This groundbreaking approach was recognized with an FDA Breakthrough Device Designation in April. The GRADIENT study will be a prospective, multicenter, randomized, controlled, open-label trial that plans to enroll patients with renal insufficiency (eGFR 15-60 ml/min) undergoing elective or urgent cardiac surgery requiring CPB. The study seeks to evaluate the safety and effectiveness of the JuxtaFlow RAD to sustain or enhance renal function during and following CPB surgery. "Achieving Breakthrough Device Designation was instrumental in securing IDE approval," noted John Erbey , Chief Executive Officer at Roivios. "This initiative is the culmination of a decade of technological and clinical advancements in addressing kidney disease management challenges. Our ongoing dialogue with the FDA is paving the way for more effective management, empowering patients to thrive. We are eager to commence IDE enrollment and explore the JuxtaFlow RAD's potential to improve surgical outcomes and enhance patient quality of life." For more information about Roivios and the JuxtaFlow Renal Assist Device, please visit Roivios.com . About JuxtaFlow RAD The JuxtaFlow RAD is a pioneering investigational device set to transform kidney support therapy. Acknowledging the harmful effects of fluid accumulation and pressure on the kidneys, Roivios has advanced beyond traditional blood filtration methods that can further stress the kidneys. By applying mild, controlled negative pressure within the kidney's collecting system, the device has the potential to maintain and improve filtration and support recovery. This novel approach holds promise for a compelling value proposition by preserving kidney function and expediting patient recovery, ultimately reducing hospital stays and associated costs. Equipped with a proprietary specialized catheters and pump, the device optimizes kidney function during critical recovery periods, such as post-surgery. Currently, the JuxtaFlow RAD is under investigation and is not available for sale in any geography. About Roivios Roivios is a clinical-stage medical device company committed to pioneering solutions for kidney health. Our lead product, the JuxtaFlow Renal Assist Device (RAD), is designed to preserve kidney function and offer a proactive approach to managing kidney disease. We aim to demonstrate improved renal outcomes, potentially reducing the need for dialysis, and lowering healthcare costs. Holding proprietary patents in key kidney technologies, we aim to revolutionize kidney disease management. With plans to extend its application beyond kidney disease to various medical settings, Roivios is preparing for a transformative U.S. launch, aiming to redefine kidney disease management and improve patient quality of life. Discover more at roivios.com . This release contains forward-looking statements subject to risks and uncertainties. Actual results may differ significantly. Media Contact : Kelly Krueger , Krueger PR, kelly@kruegerpr.com View original content to download multimedia: https://www.prnewswire.com/news-releases/fda-grants-ide-approval-for-the-pivotal-trial-of-the-juxtaflow-renal-assist-device-rad-302336698.html SOURCE Roivios, ltd